Pasithea Therapeutics Corp
KTTA
NASDAQ
Biotechnology
$0.48
USD
0.00 (+0.52%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $15.97M
Volume 39.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-19.73M
TTM
-45.0%
YoY
Operating Cash Flow
$-16.94M
TTM
-33.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.0 | 1.7 | 1.8 | 7.5 | 1.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.7 | 3.8 | 3.1 | 10.3 | 4.9 |
Operating Income | -3.7 | -3.8 | -3.1 | -10.3 | -4.9 |
EBITDA | -3.5 | -3.6 | -2.9 | -10.1 | -4.7 |
Other Income / Expense | 0.1 | 0.0 | 0.0 | -0.0 | 1.5 |
Total Other Income / Expense | 0.1 | 0.1 | 0.1 | 0.1 | 2.0 |
Income Before Income Taxes | -3.6 | -3.7 | -3.0 | -10.1 | -2.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -3.6 | -3.7 | -3.0 | -10.1 | -2.9 |
Consolidated Net Income / Loss | -3.6 | -3.7 | -3.0 | -10.1 | -2.9 |
Net Income Attributable to Common Shareholders | -3.6 | -3.7 | -3.0 | -10.1 | -2.9 |
Basic EPS | -$1.61 | -$0.66 | -$0.41 | -$0.79 | -$0.12 |
Diluted EPS | -$1.61 | -$0.66 | -$0.41 | -$0.79 | -$0.12 |
Basic Shares Outstanding | 2.2M | 5.6M | 7.4M | 12.8M | 24.3M |
Diluted Shares Outstanding | 2.2M | 5.6M | 7.4M | 12.8M | 24.3M |